Physician profile
Samar Harris
NPI 1154532976
$4,102.87
in general payments reported to CMS, 2019-2025
23 companies · $797 in 2025
The $797 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.54 · 2021: $280 · 2022: $740 · 2023: $1,008 · 2024: $1,262 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,066.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,442.58 | 2021-2025 | |
| Celgene Corporation | $731.21 | 2022-2024 | Zeposia |
| Genzyme Corporation | $295.28 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $270.95 | 2021-2024 | Entyvio, Gattex, Eohilia |
| Enterra Medical, INC. | $218.27 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $181.35 | 2021-2024 | Dificid |
| Evoke Pharma, INC. | $144.22 | 2022-2025 | Gimoti |
| Ardelyx, INC. | $142.54 | 2024-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $97.95 | 2022-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.82 | 2020-2025 | Relistor, Xifaxan |
| Regeneron Healthcare Solutions, INC. | $89.91 | 2022-2025 | Dupixent |
| Medtronic, INC. | $79.12 | 2022-2025 | Pillcam |
| Lilly USA, LLC | $55.56 | 2024 | Omvoh |
| Janssen Biotech, INC. | $46.37 | 2023-2025 | Stelara, Tremfya |
| Intercept Pharmaceuticals, INC. | $41.45 | 2023-2025 | Ocaliva |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $34.58 | 2025 | Pancreaze |
| American Regent | $32.34 | 2025 | Injectafer |
| Braintree Laboratories, INC. | $26.18 | 2023 | Sutab |
| Redhill Biopharma INC. | $20.60 | 2022 | |
| Perspectum Diagnostics Ltd | $18.20 | 2022 | |
| Integra Lifesciences Corporation | $16.31 | 2024 | Acclarent Aera |
| Olympus America INC. | $15.44 | 2021 | |
| Boston Scientific Corporation | $5.64 | 2025 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samar Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.